Skip to main content

RegMedNet is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Topics
    • CAR-T
      • Stem cells
      • Cell therapy
      • Gene therapy
      • Gene editing
    • Cancer
      • Preclinical research
      • Tissue engineering
      • 3D printing
      • Biobanking
    • Clinical trials & funding
      • Manufacturing & scale-up
      • Regulation & policy
      • Industry developments

    Follow us on social media

  • Explore content
    • News
      • The week in cell therapy
      • Spotlights
      • In Focus
      • Interviews
      • Opinion
      • Report
      • App Notes & White Papers
    • eBooks
      • Webinars
      • Podcasts
      • Videos
      • Infographics
      • Partners
      • Events
      • Events news
      • Glossary

    Follow us on social media

  • Our journals
    • Our journals
    • Journal content
    • Journal articles

    Follow us on social media

  • Register
From research to clinical production: scaling iPSC and extracellular vesicle processes 13 days 18 hours 11 mins 57 secs REGISTER NOW

RegMedNet at ISCT 2017

16 May 2017
Written by RegMedNet
Cell therapy Report Spotlight on cell therapy regulation Upcoming & past events

RegMedNet brings you a roundup of the hot topics from the International Society for Cellular Therapy (ISCT)’s 23rd Annual Meeting in London, UK.

Discover what presentations were the most popular during the 4 days of ISCT 2017, what was exhibited and who attended.

Did you attend ISCT 2017? What did you enjoy most?

Where would you like to meet RegMedNet and Regenerative Medicine next?

Top content

  • Cell therapy weekly: investigational AAV-based gene therapy for FSHD completes enrollment
  • Phase I/II Parkinson’s disease cell therapy trial achieves primary endpoint
  • Novel gene therapy harnesses brain’s glymphatic system for targeted delivery

Related tags

ISCT
Previous article Next article

Related articles

2 JUN 2020 CELL THERAPY
Going virtual for ISCT 2020: an interview with John Rasko
5 FEB 2019 CELL THERAPY
Keeping patients safe from unproven cell therapies: an interview with the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies
17 JUN 2020 CELL THERAPY
ISCT 2020: conference highlights
computer-generated image of a virus
10 JUN 2020 COVID-19
COVID-19 and cell therapy: an interview with Daniel Weiss
ISCT 2020: emerging issues in unproven cell therapies – an interview with Laertis Ikonomou
8 SEP 2020 REGULATION & POLICY
ISCT 2020: emerging issues in unproven cell therapies – an interview with Laertis Ikonomou
14 APR 2026 UPCOMING & PAST EVENTS
Our top picks for ISCT 2026
  • About
  • Advertising & Sponsorship
  • Expert Panel
  • Permissions & content ownership policy
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

RegMedNet is powered by Taylor & Francis Group

RegMedNet, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 RegMedNet